Canada markets closed

Ardelyx, Inc. (ARDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5915-0.0078 (-1.30%)
At close: 04:00PM EDT
0.6190 +0.03 (+4.65%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5993
Open0.5900
Bid0.6001 x 1800
Ask0.6101 x 1800
Day's Range0.5900 - 0.6290
52 Week Range0.4900 - 8.2470
Volume12,623,539
Avg. Volume3,607,598
Market Cap85.53M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-1.3610
Earnings DateAug 11, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.14
  • Zacks

    Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

    Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

    CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. “We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer

  • Zacks

    Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates

    Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?